Somagenetix
Somagenetix is a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders. Their innovative platform utilizes lentivirus-transduced stem cells to provide safe, effective, and potentially one-time treatments for over 50 known genetic disorders. With a focus on safety, specificity, and long-term efficacy, they aim to cure a wide range of inherited diseases, significantly improving patients' lives worldwide.
Industries
Nr. of Employees
small (1-50)
Somagenetix
In der Breiti 2, 8047 Zürich, Switzerland
Products
SGX-001
Lentiviral ex vivo gene therapy candidate developed for p47 Chronic Granulomatous Disease (p47-CGD); progressed through preclinical GLP studies and planned for clinical entry.
SGX-001
Lentiviral ex vivo gene therapy candidate developed for p47 Chronic Granulomatous Disease (p47-CGD); progressed through preclinical GLP studies and planned for clinical entry.
Expertise Areas
- Gene therapy for phagocyte disorders
- Ex vivo hematopoietic stem cell modification
- Preclinical GLP study execution
- Clinical development planning for gene therapies
Key Technologies
- Lentiviral vector delivery
- Ex vivo HSC transduction
- Cell-type restricted transgene expression
- GLP preclinical animal models
News & Updates
Somagenetix AG announced the initial closing of its Series A financing round, raising CHF 10 million, led by Vi Partners. The funds will support the advancement of their gene therapy candidate SGX-001 into clinical trials for CGD, a serious immune deficiency.
Somagenetix AG announced the initial closing of its Series A financing round, raising CHF 10 million, led by Vi Partners. The funds will support the advancement of their gene therapy candidate SGX-001 into clinical trials for CGD, a serious immune deficiency.